European tuberculosis diagnosis and treatment market is anticipated to grow at a CAGR of around 1.9% during the forecast period. There is impressive progress in the tuberculosis diagnostic and treatment in the past decade, however, tuberculosis (TB) is still a public health concern in the European Region. Countries outside of the European Union (EU) and European Economic Area (EEA) still suffer from high rates of TB and multidrug-resistant (MDR) TB, while EU/EEA countries have a significant number of TB cases among vulnerable population groups, such as people of foreign origin and prisoners. TB disease affects men more than women and those gaps in case detection and reporting are higher among men.
Request a Free Sample of our Report on European Tuberculosis Diagnosis and Treatment Market: https://www.omrglobal.com/request-sample/european-tuberculosis-diagnosis-treatment-market
Due to a large number of TB death cases in Europe, the government are taking initiatives and including guidelines in each nation to improve the diagnostic and treatment methods across Europe. Guidelines are predominantly available in high-income countries with established LTBI (Latent TB Infection) screening programmers. According to World Health Organization (WHO), in 2018, A total of 1.5 million people have mortality from TB (including 251 000 people with HIV). Across the globe, TB is one of the top 10 causes of mortality and the leading cause from a single infectious agent (above HIV/AIDS).
European tuberculosis diagnosis and treatment market is segmented on the basis of drug type and diagnosis. Based on drug type, the market is segmented into first-line drugs and second line drugs. Based on diagnosis, the market is segmented into laboratory testing, nucleic acid amplification test, mantoux test, radiography and drug susceptibility testing.
The key players that are active in the market include Abbott Laboratories, Becton, Dickinson and Co., BioMérieux SA, EPISTEM HOLDINGS PLC, GlaxoSmithKline PLC, Hain Lifescience GmbH, Johnson & Johnson, OTSUKA NOVEL PRODUCTS GMBH, Sandoz Inc. and Sanofi Inc.
A Full Report of European Tuberculosis Diagnosis and Treatment Market is Available at https://www.omrglobal.com/industry-reports/european-tuberculosis-diagnosis-treatment-market
European Tuberculosis Diagnosis and Treatment Market
By Drugs Type
- First Line Drugs
- Second Line Drugs
- Laboratory Testing
- Nucleic Acid Amplification Test
- Mantoux Test
- Drug Susceptibility Testing
- United Kingdom
- Rest of Europe
- Abbott Laboratories
- Becton, Dickinson and Co.
- BioMérieux SA
- EPISTEM HOLDINGS PLC
- GlaxoSmithKline PLC
- Hain Lifescience GmbH
- Johnson & Johnson
- OTSUKA NOVEL PRODUCTS GMBH
- Sandoz Inc.
- Sanofi Inc.
For More Customized Data, Request for Report Customization @ https://www.omrglobal.com/report-customization/european-tuberculosis-diagnosis-treatment-market
Orion Market Research (OMR) is a market research and consulting company known for its crisp and concise reports. The company is equipped with an experienced team of analysts and consultants. OMR offers quality syndicated research reports, customized research reports, consulting and other research-based services.
For More Information, Visit https://www.omrglobal.com/
Company Name: Orion Market Research
Contact Person: Mr. Anurag Tiwari
Contact no: +1 646-755-7667, +91 780-304-0404